Product Information
FUROSEMIDE 20 MG/2 ML VIAL is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.4901 per ML under NDC 00143915525. Its NADAC has been published 87 times since Feb 5, 2025.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AP.
Strength
10 mg/mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00143915525
Classification
Generic
Dosage Form
INJECTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
FUROSEMIDEApproval Type
New Drug (NDA)
FDA Application
NDA018267FDA Approved
Before 1982
TE Code
AP
On Market Since
5/31/2024
Pharmacological Classes
Price Statistics
The NADAC for FUROSEMIDE 20 MG/2 ML VIAL has been published 87 times since Feb 5, 2025, and over the history we have for it it has risen 20.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4901 per ML |
|---|---|
| All-time high | $0.4901 (Sep 30, 2026) |
| All-time low | $0.3473 (Dec 17, 2025) |
| 52-week high | $0.4901 |
| 52-week low | $0.3473 |
| Median price | $0.4073 |
| Average price | $0.3985 |
| Largest weekly change | -8.0% (Aug 20, 2025) |
| Weeks tracked | 87 |
| Tracking since | Feb 5, 2025 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 48% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Furosemide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Loop Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FUROSEMIDE 20 MG/2 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for FUROSEMIDE 20 MG/2 ML VIAL, manufactured by Hikma Pharmaceuticals USA Inc., is $0.4901 per ML (NDC 00143915525), effective Sep 30, 2026.
How has the price of FUROSEMIDE 20 MG/2 ML VIAL changed over time?
Over the history we have for it, the NADAC for FUROSEMIDE 20 MG/2 ML VIAL has risen 20.3%. It has been tracked across 87 weekly CMS publications since Feb 5, 2025.
What are the highest and lowest recorded NADAC prices for FUROSEMIDE 20 MG/2 ML VIAL?
Since Feb 5, 2025, the NADAC for FUROSEMIDE 20 MG/2 ML VIAL has ranged from a low of $0.3473 (Dec 17, 2025) to a high of $0.4901 (Sep 30, 2026), with a median of $0.4073 per ML.
Are there cheaper alternatives to FUROSEMIDE 20 MG/2 ML VIAL?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FUROSEMIDE 40 MG/4 ML VIAL, is $0.2525 per ML — about 48% below FUROSEMIDE 20 MG/2 ML VIAL.
Who manufactures FUROSEMIDE 20 MG/2 ML VIAL?
FUROSEMIDE 20 MG/2 ML VIAL (NDC 00143915525) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.